摘要
目的：探讨午伐他汀对慢性阻塞性肺疾病（COPD）患者诱导痰中巨噬细胞表达的影响方法：选择我院门诊COPD缓解期患者53例，给予常规治疗21例，辛伐他汀20mg／d治疗32例，比较治疗前和治疗12周后患者诱导痰中巨噬细胞（M％）、中性粒细胞（N％）百分比和CD68的表达。结果：12周后中伐他汀组诱导痰巨噬细胞（M％）11．5±6．32较治疗前4．8±3．71升高，差异有统计学意义（P〈0．05）；中性粒细胞百分比（N％）56．3±5．56较治疗前75．43±13．92明显降低（P〈0．01）；CD68表达阳性21例较治疗前7例升高（P〈0．05）；常规治疗组所有CD68及巨噬细胞、中性粒细胞百分比均无显著改善（P均〉0．05）。结论：辛伐他汀可刺激气道巨噬细胞CD68的表达，减轻COPD患者全身性炎症反应.
OBJECTIVE： To study the expressions of CD68 on alveolar macrophages in induced sputum of patients with chronic obstructive pulmonary diseases （COPD） by sirnvastatin. METHOD： Fifty - three stable COPD patients were randomly divided into simvastatin- treatment group （n = 32, orally siren simvasmtin tablets for 12 weeks in addition to basic therapy, 20rag, qd） and control group （ n = 21, siren usual reed - ieation）. Percentage of leukoeytes （ N% ） , percentage of Alveolar macrophage and expression of CD68 positive macruphage in induced sputum at pre - post - treatment were compared. RESULTS ： After the treatment the N% 56. 3 ±5.56 dropped significantly in the simvastatin group cormpared with that before treatment 75.43 ± 13.92 （ P 〈0.01 ） ; Percentage of Alveolar maerophage and expression of CD68 positive macrophage 11.5 ± 6. 32 vs 4. 8 ± 3.71, 21 vs 7 （ P 〈 0.05 ） were significantly decreased than those before treatment. There were significant difference （P 〈0.05 ） . The control group showed no significant change in any parameters before and after 12 weeks treatment （P 〉 0. 05）. CONCLUSION： Simvastafin can increase expression of CD68 positive macrophage and alleviate systemic inflammation and relieve symptoms in patients with COPD.
出处
《国际老年医学杂志》
2013年第6期250-253,共4页
International Journal of Geriatrics
